open access

Vol 11, No 4 (2007)
Prace oryginalne
Published online: 2007-09-07
Get Citation

Hypotensive efficacy of eprosartan in postmenopausal women

Joanna Niegowska, Magdalena Niegowska, Bogdan Jasiński
Nadciśnienie tętnicze 2007;11(4):328-334.

open access

Vol 11, No 4 (2007)
Prace oryginalne
Published online: 2007-09-07

Abstract

Background The aim of the study was to evaluate the efficacy of eprosartan monotherapy treatment in postmenopausal women with essential hypertension.
Material and methods 52 women with essential hypertension aged 52.8 ± 3.4 years who had last menstrual period 2 years ago. The women were not treated with any hypertensive medication for at least 1 month. Women received eprosartan (Teveten) 600 mg/daily between 6.30-7.00 am. Ambulatory blood pressure monitoring was performed with SpaceLabs 90207 before treatment, 6 and 12 weeks of therapy with eprosartan.
Results Twelve weeks of eprosartan treatment resulted in the lowest values of both SBP and DBP during day and night. After 6 weeks of eprosartan treatment in comparison with the period before treatment the significant reduction of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during day and night was observed. During next 6 weeks further, statistically significant reduction of SBP only during day was observed. After 12 weeks of eprosartan treatment the lowest HT was also observed. The differences were statistically significant when compared to HT noted before treatment during day and night. The following 6 weeks of treatment showed statistically significant decreased values only during day.
Conclusions Eprosartan is an effective hypotensive monotherapy in postmenopausal women and showes more intensive hypotensive effects after 12 weeks of treatment with a stable dose than after 6 weeks of treatment. Eprosartan presents a good effect on the heart rate during day but especially during night.Arterial Hypertension 2007, vol. 11, no 4, pages 328-334.

Abstract

Background The aim of the study was to evaluate the efficacy of eprosartan monotherapy treatment in postmenopausal women with essential hypertension.
Material and methods 52 women with essential hypertension aged 52.8 ± 3.4 years who had last menstrual period 2 years ago. The women were not treated with any hypertensive medication for at least 1 month. Women received eprosartan (Teveten) 600 mg/daily between 6.30-7.00 am. Ambulatory blood pressure monitoring was performed with SpaceLabs 90207 before treatment, 6 and 12 weeks of therapy with eprosartan.
Results Twelve weeks of eprosartan treatment resulted in the lowest values of both SBP and DBP during day and night. After 6 weeks of eprosartan treatment in comparison with the period before treatment the significant reduction of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during day and night was observed. During next 6 weeks further, statistically significant reduction of SBP only during day was observed. After 12 weeks of eprosartan treatment the lowest HT was also observed. The differences were statistically significant when compared to HT noted before treatment during day and night. The following 6 weeks of treatment showed statistically significant decreased values only during day.
Conclusions Eprosartan is an effective hypotensive monotherapy in postmenopausal women and showes more intensive hypotensive effects after 12 weeks of treatment with a stable dose than after 6 weeks of treatment. Eprosartan presents a good effect on the heart rate during day but especially during night.Arterial Hypertension 2007, vol. 11, no 4, pages 328-334.
Get Citation

Keywords

eprosartan; hypotensive efficacy; 24-hour ABPM; women

About this article
Title

Hypotensive efficacy of eprosartan in postmenopausal women

Journal

Arterial Hypertension

Issue

Vol 11, No 4 (2007)

Pages

328-334

Published online

2007-09-07

Bibliographic record

Nadciśnienie tętnicze 2007;11(4):328-334.

Keywords

eprosartan
hypotensive efficacy
24-hour ABPM
women

Authors

Joanna Niegowska
Magdalena Niegowska
Bogdan Jasiński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl